What's
New at
Labrix?
DPD
Simple, non-invasive urine test to track your patients' rate of bone loss. Pair this test with hormone and adrenal panels.
Learn more here.
DNA
FindWhyTM Weight Control Panel for Genetic Tendencies. DNA sample is collected from a non-invasive cheek swab.
Learn more here.
DHT
Acne, hair loss or hirutism a concern for your patients? Consider adding (DHT)
testing to their saliva test.
Coming soon!
October 3, 2014
Breast Health and Birth Control

Themed awareness months are not uncommon, but with the onset of October comes what is perhaps the most well-known of them all - Breast Cancer Awareness Month. The most commonly diagnosed cancer in women, current statistics demonstrate that 1 in 8 women will be diagnosed with breast cancer in their lifetime. Well known risk factors include a family history of breast cancer, age, alcohol consumption, and obesity. While these risk factors are well known, the most commonly discussed among providers and patients may be hormonal relationships to breast cancer and breast cancer risk. Use of the words “hormones” and “breast cancer” conjures thoughts of hormone replacement therapies and the Women’s Health Initiative; however a more commonly utilized hormone therapy is known to affect breast cancer risk as well – hormonal birth control. 99% of sexually active women between the ages of 15 and 44 have used some form of birth control beyond family planning, the most common of these being the birth control pill. What do we currently know about birth control and breast cancer risk?

  • Current or recent use of birth control pills is associated with a slightly increased risk of breast cancer
  • This increased risk is not seen 10 years post birth control pill use
  • Current longer-term users of Depo Provera have a possible increased risk
  • Limited information is available in regards to the birth control patch and vaginal ring

While some forms of birth control may slightly increase a woman’s risk of breast cancer, younger age (when women are commonly using birth control) and premenopausal status puts women at a low risk. Once discontinued, the increased risk does decrease over time and diminishes at 10 years. While this is the current understanding of hormonal birth control’s association with breast cancer risk, it is important to note that the majority of information comes from studying previous formulations and minimal information is available based on today’s lower-dose formulations.

Labrix is committed to educating healthcare providers about breast health and how balancing hormones can benefit women's (and men's) health and well-being. Learn more about breast health with Labrix medical director Dr. Jay Mead, MD, FASCP at the American Functional Medicine Association (AFMA) conference, November 6-9 in Atlanta GA. To receive $100 off registration, click here and use code jm2 when registering.

Labrix also invites you to join Dr. Mead, as well as Labrix CEO Dr. Erin Lommen ND, staff physicians and special guests at Labrix Advanced Workshop (LAW) on January 24 and 25, 2015. Discussions and presentations will provide additional clinical insight to address the most prevalent and challenging conditions that arise in clinical practice, including hormone imbalance and replacement therapies, anxiety, menopause, andropause, pain, fatigue and much more. Registration is open now! Click to register.

References:

Labrix Celebrates its 10th Anniversary!

Labrix co-founders Dr. Erin Lommen and Dr. Jay Mead sit down for a short interview and discuss the company's first ten years, as well as its bright future with diagnostic testing.




https://www.youtube.com/watch?v=dKU1ZxcuvOY



Labrix
Advanced Workshop
Las Vegas, NV
Jan 24-25, 2015

Registration is just $199 for Labrix Advanced Workshop (LAW). Register for LAW today.

AARM
Santa Fe, NM
Oct. 8-12, 2014

Labrix' co-founders Dr. Erin Lommen and Dr. Jay Mead will be speaking at AARM.

To receive $200 discount off your registration fee, use code SPEAKER200 when registering for the conference.


AFMA
Atlanta, GA
Nov 6-9, 2014

Labrix' co-founders Dr. Erin Lommen and Dr. Jay Mead will be speaking at AFMA.

To receive $100 off your registration, use code EL2 or JM2 when registering for the conference.